ArticleBMC cancer2025
A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A single-center retrospective study evaluating the efficacy of anlotinib plus temozolomide for recurrent glioma based on real-world data.Translational cancer research · 2026Article
- Anlotinib-temozolomide combination achieves durable response in multimodal-resistant primary breast angiosarcoma with skull base metastasis and dural involvement: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of anlotinib plus temozolomide (TMZ) as a first-line treatment for recurrent/Residual glioma.
methodsThirty eligible patients who either relapsed after the standard chemoradiotherapy regimen (TMZ plus radiotherapy) or had macroscopic residual tumors due to involvement of eloquent brain areas were enrolled between March 2018 and January 2021. Patients received anlotinib (12 mg once daily, 14 days on/7 days off) in combination with TMZ (200 mg/m², 5 days on/23 days off) until disease progression or unacceptable toxicity. The efficacy was evaluated using the Response Assessment in Neuro-Oncology(RANO) criteria for high-grade gliomas. Safety was assessed using the NCI-CTCAE 4.0. Survival outcomes were estimated with the Kaplan-Meier method and compared using the log-rank test.
resultsBy April 2023, the median follow-up time was 28.1 ± 5.07 months(95% CI:18.20-38.06). The median overall survival (OS, measured from recurrence to death or last follow-up) was 17.87 ± 4.29 months (95% CI: 9.46–26.28). 1-year, 1.5 year, 2-year OS rates were 60.0%, 46.7%, and 36.7%, respectively. The median progression-free survival (PFS, measured from initiation of Anlotinib plus TMZ) was 7.83 ± 0.82 months(95% CI, 6.22–9.44). The 6-month, 1-year PFS rates were 63.3% and 36.7%, respectively. Univariate analysis showed that patients with WHO grade 2 gliomas had significantly longer median OS and PFS compared with those with grade 3 or 4 gliomas (grade 2: 30.45 ± 4.32, grade 3: 15.07 ± 5.72, grade 4: 9.21 ± 1.90, P = 0.035). Patients aged ≤ 55 years had significantly longer median PFS than those > 55 years (12.97 ± 1.71 vs. 7.33 ± 1.95. p = 0.010), although the difference in OS did not reach statistical difference (19.90 ± 6.29 m vs. 10.53 ± 1.68 m, p = 0.106). Additionally, sex, 1p/19q and IDH mutations were not significant negative predictors of OS or PFS. Multivariate analysis further indicated that age, pathological grade, and IDH mutation were not independent predictors of PFS or OS in recurrent glioma.
conclusionAnlotinib combined with TMZ demonstrated potential efficacy for recurrent glioma, as reflected in observed OS and PFS outcomes, and demonstrated an acceptable tolerability profile in this patient cohort. Larger randomized controlled trials are warranted to confirm these findings and further define the role of anlotinib plus TMZ for the management of recurrent glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.